News – Page 5 – FSD Pharma

Blog

FSD Pharma Issues 40,000,000 Stock Options to Director Dr. Raza Bokhari Conditional on Nasdaq Listing

TORONTO, September 11, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) announces that pursuant to its Stock Option Plan, the Board approved the grant of 3,000,000 stock options for class B subordinate voting shares of the Company (the “Options”) on August 14, 2018 to Dr. Raza Bokhari following his appointment as a Director. The Options vest immediately and are exercisable at a price of $0.13 for a period of five years. The Company has also cancelled 15,000,000 stock options that had been previously issued at $0.05. Continue Reading

FSD Pharma Congratulates High Tide Ventures for Selection as Supplier to Ontario Cannabis Retail Corporation

TORONTO – September 7, 2018/CNW/ – FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) today congratulated High Tide Ventures Inc. (“High Tide”) for the selection of its wholly-owned subsidiary Famous Brandz Inc. (“Famous Brandz”) as an accessories supplier to the Ontario Cannabis Retail Corporation, operating as the Ontario Cannabis Store (“OCS”). Under the announcement by the OCS on September 5, 2018, Famous Brandz was one of ten accessories suppliers newly-selected to supply accessories to the adult-use market in the Province of Ontario.

“This is a well-deserved acknowledgement of the capability of High Tide and its subsidiary Famous Brandz to supply some of the most innovative cannabis accessories to the adult-use market in Canada’s largest province. FSD applauds High Tide and wishes the company much success in its latest supply agreement,” said Zeeshan Saeed, EVP and Director of FSD Pharma.

FSD Pharma previously announced that its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”) had entered into a non-binding memorandum of understanding (“MOU”) with High Tide dated July 18, 2018 to supply the Saskatchewan market on a wholesale basis with up to 5,000,000 grams of cannabis products over the next year when available. FSD Pharma will continue to work collaboratively with High Tide as a supplier of cannabis products and accessories across Canada. Continue Reading

FSD Pharma Breaks All-time Daily Volume Record and Makes History Again

TORONTO, September 5, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9), is pleased to report that on September 4, 2018 the Company traded an aggregate total of exactly 151,183,895 shares. FSD traded 106,397,927 Class B subordinate voting shares on the Canadian Securities Exchange (“CSE”), 5,883,500 on AQC-Lit, 5,180,500 on AQC-Neo, 501,526 on CXC, 751,300 on CX2, 8,781,217 on CXD, 382,000 on Lynx, 8,631,000 on Omega and 14,674,925 on MatchNow. This is the largest total quantity of share volume traded by a CSE listed issuer by over 33.6% above the recorded all-time high of 113,135,861 achieved by FSD on its first day of trading, as confirmed by the CSE.

The company wishes to again thank all its shareholders and stakeholders for their support to date, which has resulted in yet another record-breaking achievement in the Canadian cannabis investment marketplace.
Continue Reading

FSD Pharma Reports Q2 Results

TORONTO, August 30, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTC: FSDDF) reported its financial and operational results for the second quarter of fiscal 2018, ended June 30th, 2018. These filings are available for review on the Company’s SEDAR profile at www.sedar.com.
Highlights of The Company:
• Completion of 25,000 square feet solely owned by FSD Pharma
• Construction underway of the Auxly partnership Phase 1 approx. 220,000 Sq Ft expansion at Cobourg, Ontario, with a total budget of $55,000,000
• Construction of Phase 1, approx. 105,000 Sq FT by Cannara partnership at the facility close to Montreal, Quebec underway
• The first cannabis crop has been harvested and tested which is an essential step in the granting of a sales license
• Strong Cash position at June 30, 2018 with $31.7 Million Cash and even more in liquid assets
• No Debt

The construction in Coburg, Ontario remains on schedule with cultivation expected to commence in the first half of 2019. The Company maintained a strong balance sheet with cash of $31,700,000, no debt, significant assets and continues to execute on management’s vision of becoming the largest indoor grow facility in the world with total grow capacity, once completed, in excess of 3,000,000 square feet. With an expected annual output of 400,000,000 grams of which FSD Pharma would benefit 200,000,000 grams.
FSD Pharma continues to make Strategic early stage investments in the Cannabis industry with like minded companies that 1) provide excellent investment potential and 2) will assist FSD strategically in its business. An example of this is evidenced by this quarters mark to market asset revaluation of FSD’s holding in Cannara Biotech resulting in a $7,500,000 gain… Continue Reading

FSD Pharma reports positive pre-clinical results for proprietary CBD combination product

TORONTO, Aug. 23, 2018 /PRNewswire/ – FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) reports today that its strategic R&D partner, SciCann Therapeutics Inc. (“SciCann”), has achieved positive results in a pre-clinical efficacy study of its proprietary “Steady Stomach” CBD combination product for Inflammatory Bowel Disease (IBD). Under the terms of the agreement between FSD and SciCann, FSD Pharma holds exclusive marketing and distribution rights for the “Steady Stomach” product in Canada.

The “Steady Stomach” product is a patent-pending combination of Cannabidiol (CBD) together with additional synergistic factors that potentiate and activate the anti-inflammatory properties of CBD, thus making it more effective as a potential treatment for IBD disorders. All active ingredients of the “Steady Stomach” formulation are natural food-grade compounds, thus qualifying it as a CBD food supplement product. Previously completed tox studies in rodents performed by SciCann has demonstrated very high safety profile for the combination product, without any observed adverse events. Continue Reading

FSD Pharma Completes Harvest and Microbial Testing of First Lot

TORONTO, August 21, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) is pleased to announce that its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), a licensed cannabis producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”), completed the harvest of its first lot of cannabis and successfully passed microbial testing required by Health Canada under the ACMPR and will be harvesting its second lot this week so as to conduct full analytical testing, thereby positioning FV Pharma to request a Pre-Sales License Inspection from Health Canada. The Pre-Sales License Inspection is the last step prior to the issuance of a Sales License under the ACMPR. Continue Reading

Fsd Pharma and Scicann Therapeutics Launch Clinical Research Program in Israel

CSE: HUGE
OTC: FSDDF
FRA: 0K9

TORONTO, August 16, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9), announced today the launch of a clinical research collaborative program in Israel, via its strategic R&D partner, SciCann Therapeutics Inc. (“SciCann”)

This comprehensive clinical research program will be executed through SciCann’s strategic alliance and collaboration agreement with Mor Research Applications Ltd. (“Mor”) – the technology transfer office and commercial arm of Clalit Healthcare Services, Israel’s largest medical insurer and healthcare provider, which operates a network of 14 full scale hospitals throughout Israel, employs over 9,000 physicians and serves the healthcare needs of over 50% of Israel’s population. Continue Reading

FSD Pharma Announces Listing on Frankfurt Stock Exchange

CSE: HUGE
OTC: FSDDF
FRA: 0K9

TORONTO, August 14, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTC: FSDDF) announced today that its subordinate voting shares are now listed on the Frankfurt Stock Exchange (“FRA”) and are trading under the “WKN: A2JM6M” and the ticker symbol “0K9.” The Company’s subordinate voting shares continue to be listed on the Canadian Stock Exchange (“CSE”) under the ticker symbol “HUGE” and on the OTC in the US under the ticker symbol “FSDDF.” Continue Reading

FSD Pharma Inc. announced appointment of Dr. Raza Bokhari as new director

TORONTO, August 2, 2018 /CNW/ – FSD Pharma Inc. (“FSD“) (CSE: HUGE) (OTC: FSDDF), is pleased to announce the appointment of Dr. Raza Bokhari to its Board of Directors, effective immediately.

Dr. Bokhari currently serves as the Chairman & CEO of PCL, a global diagnostic provider of addiction screening and opioid prescription medication monitoring, including designer drugs and synthetic cannabinoids. He is also the managing partner of RBx Capital, LP.  Recipient of Philadelphia Business Journal’s “40 under 40” award, physician turned entrepreneur, Dr. Bokhari has over the past several years developed outstanding expertise in aggregating and accelerating life sciences and healthcare services companies. He has a vast knowledge base of developing creative concepts, implementing programs and forming strategic alliances. An effective “change agent”, with several years of experience and expertise in start-up and turn-around businesses, he is adept at turning around financially struggling companies. Dr. Bokhari recognizes the special role of private equity funds, venture capital money, and leveraged debt partners in executing accelerated growth trends in healthcare services and cancer diagnostics and therapeutics. Continue Reading

FSD Pharma Surpasses One Billion Shares Traded and Makes History With Annual CSE Volume Trading Record in Less Than Two Months

TORONTO, June 20, 2018 /PRNewswire/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTC: FSDDF), is pleased to report that it has traded over one Billion Class B subordinate voting shares and has broken the one year consecutive days of trading record on the Canadian Securities Exchange (“CSE”) in less than two months of trading. During the period of May 29, 2018 to July 18, 2018, the Company traded exactly 1,028,297,481 Class B subordinate voting shares on the Canadian Securities Exchange (“CSE”). Comparatively, the largest amount traded prior on the CSE in a one year period of consecutive days was 989,295,522. This is the largest total quantity of share volume ever traded by a CSE listed issuer within one year of consecutive days of trading as confirmed by the CSE. Continue Reading